SCHEMBL1154092

SCHEMBL1154092

CCCCOc1ccc(Cl)cc1C(=O)OC

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.54
CNR1 P21554 1/20 0.54
MAPT P10636 3/20 0.52
ALDH1A1 P00352 3/20 0.52
TDP1 Q9NUW8 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
MEN1 O00255 2/20 0.52
GAA P10253 2/20 0.52
KMT2A Q03164 2/20 0.52
LMNA P02545 1/20 0.50
HPGD P15428 3/20 0.49
TSHR P16473 1/20 0.49
ABL1 P00519 1/20 0.49
S1PR4 O95977 1/20 0.48
HSP90AA1 P07900 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP2C9 P11712 1/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4360418 0.93 LMNA (0.51) KDM4ECNR1MAPTALDH1A1L3MBTL1
SCHEMBL2796366 0.88 MAPT (0.52) KDM4ECNR1MAPTALDH1A1L3MBTL1
SCHEMBL2799514 0.87 MAPT (0.55) KDM4EMAPTALDH1A1MEN1GAA
SCHEMBL1505120 0.87 S1PR4 (0.52) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL929622 0.87 MAPT (0.50) KDM4EMAPTALDH1A1MEN1GAA
SCHEMBL6421995 0.87 SLC6A4 (0.51) KDM4ECNR1MAPTALDH1A1L3MBTL1
SCHEMBL17040919 0.86 SMN1; SMN2 (0.58) MAPTALDH1A1TDP1L3MBTL1MEN1
Hydrochloric Acid SCHEMBL1505095 0.86 MAPT (0.50) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL22175914 0.86 MAPT (0.50) KDM4EMAPTALDH1A1MEN1KMT2A
SCHEMBL22175893 0.86 ALDH1A1 (0.60) KDM4EMAPTALDH1A1TDP1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8299123-B2 CCR10 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-30 US disclosed
US-8299123-B2 CCR10 antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-10-30 US disclosed
EP-2215065-B1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2012-07-11 EP disclosed
US-20110039851-A1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-02-17 US disclosed
EP-2215065-A1 CCR10 ANTAGONISTS Boehringer Ingelheim International GmbH (DE) 2010-08-11 EP disclosed
WO-2009052078-A1 CCR10 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-04-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110039851-A1 CCR10 ANTAGONISTS CCR10, CCR1, CCR4 KDM4E 3511/4885CNR1 83/4885MAPT 284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.